CA2137573A1 - Pharmaceutical compositions containing nsaid and bile acids - Google Patents
Pharmaceutical compositions containing nsaid and bile acidsInfo
- Publication number
- CA2137573A1 CA2137573A1 CA 2137573 CA2137573A CA2137573A1 CA 2137573 A1 CA2137573 A1 CA 2137573A1 CA 2137573 CA2137573 CA 2137573 CA 2137573 A CA2137573 A CA 2137573A CA 2137573 A1 CA2137573 A1 CA 2137573A1
- Authority
- CA
- Canada
- Prior art keywords
- bile acids
- bile acid
- pharmaceutical compositions
- bile
- compositions containing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
Abstract
Non-steroidal anti-inflammatory drugs, such as indomethacin, and other pharmaceutically active compounds, are formulated with bile acids or their salts and conjugates. Bile acids previously proposed for use in such formulations have placed an un-acceptable toxic load on the liver and/or cells of the gastrointestinal tract, causing abnormal liver function or cell erosion. In this invention, the bile acid is a low detergent bile acid, such as ursodeoxycholate. Stabilization of the bile acid pool results in enhanced and predictable enterohepatic recycling of NSAIDs (and other drugs) and a reduced risk of toxicity.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB929212511A GB9212511D0 (en) | 1992-06-12 | 1992-06-12 | Pharmaceutical compositions |
GB9212511.1 | 1992-06-12 | ||
PCT/GB1993/001247 WO1993025192A1 (en) | 1992-06-12 | 1993-06-11 | Pharmaceutical compositions containing nsaid and bile acids |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2137573A1 true CA2137573A1 (en) | 1993-12-23 |
CA2137573C CA2137573C (en) | 1999-01-26 |
Family
ID=10716996
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002137573A Expired - Fee Related CA2137573C (en) | 1992-06-12 | 1993-06-11 | Pharmaceutical compositions containing nsaid and bile acids |
Country Status (15)
Country | Link |
---|---|
US (1) | US5942248A (en) |
EP (1) | EP0644757B1 (en) |
JP (1) | JPH07508724A (en) |
AT (1) | ATE157865T1 (en) |
AU (1) | AU671285B2 (en) |
CA (1) | CA2137573C (en) |
DE (1) | DE69313849T2 (en) |
DK (1) | DK0644757T3 (en) |
ES (1) | ES2107038T3 (en) |
GB (1) | GB9212511D0 (en) |
GR (1) | GR3025565T3 (en) |
HK (1) | HK1002828A1 (en) |
NZ (1) | NZ253262A (en) |
SG (1) | SG63537A1 (en) |
WO (1) | WO1993025192A1 (en) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5843929A (en) * | 1996-03-22 | 1998-12-01 | Mayo Foundation For Medical Education And Research | Chemoprevention of metachronous adenomatous colorectal polyps |
AU2540397A (en) * | 1996-03-22 | 1997-10-10 | Mayo Foundation For Medical Education And Research | Combinations of an ursodeoxycholic acid compound and a nsaid for the chemopreventive protection of the colorectum |
US6046185A (en) * | 1996-07-11 | 2000-04-04 | Inflazyme Pharmaceuticals Ltd. | 6,7-oxygenated steroids and uses related thereto |
KR100578669B1 (en) * | 1997-05-29 | 2006-12-07 | 동아제약주식회사 | Transparent soft capsule with ursodeoxycholic acid |
US7772220B2 (en) * | 2004-10-15 | 2010-08-10 | Seo Hong Yoo | Methods and compositions for reducing toxicity of a pharmaceutical compound |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6245352B1 (en) * | 1999-04-27 | 2001-06-12 | Eli Lilly And Company | Pharmaceutical formulation |
US7169889B1 (en) * | 1999-06-19 | 2007-01-30 | Biocon Limited | Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin |
EP1255566A2 (en) * | 2000-02-04 | 2002-11-13 | Seo Hong Yoo | Preparation of aqueous clear solution dosage forms with bile acids |
JP2003530329A (en) * | 2000-04-07 | 2003-10-14 | ユニヴァーシティ オブ メリーランド,ボルチモア | Bile acid-containing prodrugs with increased bioavailability |
WO2002032376A2 (en) * | 2000-10-06 | 2002-04-25 | Xenoport, Inc. | Bile-acid conjugates for providing sustained systemic concentrations of drugs |
WO2002044324A2 (en) | 2000-10-06 | 2002-06-06 | Xenoport, Inc. | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs |
US20030054015A1 (en) * | 2000-12-25 | 2003-03-20 | Shinichiro Haze | Sympathetic-activating perfume composition |
US7060675B2 (en) * | 2001-02-15 | 2006-06-13 | Nobex Corporation | Methods of treating diabetes mellitus |
US6828305B2 (en) | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6828297B2 (en) | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US7713932B2 (en) | 2001-06-04 | 2010-05-11 | Biocon Limited | Calcitonin drug-oligomer conjugates, and uses thereof |
US6713452B2 (en) | 2001-06-04 | 2004-03-30 | Nobex Corporation | Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US7312192B2 (en) * | 2001-09-07 | 2007-12-25 | Biocon Limited | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
US6770625B2 (en) | 2001-09-07 | 2004-08-03 | Nobex Corporation | Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith |
US6913903B2 (en) * | 2001-09-07 | 2005-07-05 | Nobex Corporation | Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
US7030082B2 (en) * | 2001-09-07 | 2006-04-18 | Nobex Corporation | Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith |
US7166571B2 (en) * | 2001-09-07 | 2007-01-23 | Biocon Limited | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
US20050032871A1 (en) * | 2002-09-03 | 2005-02-10 | Sugen, Inc. | Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors |
US6843406B2 (en) * | 2002-09-27 | 2005-01-18 | Battelle Memorial Institute | Gas-tight metal/ceramic or metal/metal seals for applications in high temperature electrochemical devices and method of making |
US7754230B2 (en) * | 2004-05-19 | 2010-07-13 | The Regents Of The University Of California | Methods and related compositions for reduction of fat |
ES2660172T3 (en) * | 2004-05-19 | 2018-03-21 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Injectable composition comprising sodium deoxycholate |
US20060127468A1 (en) | 2004-05-19 | 2006-06-15 | Kolodney Michael S | Methods and related compositions for reduction of fat and skin tightening |
CA2910494C (en) | 2004-07-19 | 2018-10-23 | Biocon Limited | Insulin-oligomer conjugates, formulations and uses thereof |
MX2010003979A (en) | 2007-10-16 | 2010-06-02 | Biocon Ltd | An orally administerable solid pharmaceutical composition and a process thereof. |
ES2330295B1 (en) | 2008-06-06 | 2010-09-23 | Laboratorios Alcala Farma, Sl | TOPIC FORMULATION OF IBUPROFEN. |
US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
US8101593B2 (en) | 2009-03-03 | 2012-01-24 | Kythera Biopharmaceuticals, Inc. | Formulations of deoxycholic acid and salts thereof |
US8202230B2 (en) | 2009-08-20 | 2012-06-19 | Colgate-Palmolive Company | Oral care implement having a liquid collection system |
US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
WO2012112940A1 (en) | 2011-02-18 | 2012-08-23 | Kythera Biopharmaceuticals, Inc. | Treatment of submental fat |
US8653058B2 (en) | 2011-04-05 | 2014-02-18 | Kythera Biopharmaceuticals, Inc. | Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits |
KR102180667B1 (en) * | 2011-09-29 | 2020-11-20 | 피엘엑스 옵코 인코포레이티드 | Ph dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same |
JP2013071929A (en) * | 2011-09-29 | 2013-04-22 | Kobayashi Pharmaceutical Co Ltd | Gastrointestinal medicine |
US9498485B2 (en) | 2014-08-28 | 2016-11-22 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
WO2016033549A2 (en) | 2014-08-28 | 2016-03-03 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
WO2016070082A1 (en) | 2014-10-31 | 2016-05-06 | University Of Utah Research Foundation | Compositions and methods for bile acid particles |
JP2020503269A (en) | 2016-11-28 | 2020-01-30 | リポカイン インコーポレーテッド | Oral testosterone undecanoate therapy |
CA3172595A1 (en) | 2020-03-26 | 2021-09-30 | Ronald Zimmerman | Pharmaceutical carriers capable of ph dependent reconstitution and methods for making and using same |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4115313A (en) * | 1974-10-08 | 1978-09-19 | Irving Lyon | Bile acid emulsions |
US4164573A (en) * | 1975-06-13 | 1979-08-14 | Galinsky Alvin M | Composition and method for making a suppository for introducing a hypoglycemic agent into a mammal |
JPS53107408A (en) * | 1977-02-28 | 1978-09-19 | Yamanouchi Pharmaceut Co Ltd | Micellar preparation for rectal infusion |
IT1101649B (en) * | 1978-12-15 | 1985-10-07 | Lehner Ag | PROLONGED ACTION PHARMACEUTICAL COMPOSITION CONTAINING BILE ACIDS |
US4447412A (en) * | 1983-02-01 | 1984-05-08 | Bilton Gerald L | Enzyme-containing digestive aid compostions |
IL68769A (en) * | 1983-05-23 | 1986-02-28 | Hadassah Med Org | Pharmaceutical compositions containing insulin for oral administration |
US5288498A (en) * | 1985-05-01 | 1994-02-22 | University Of Utah Research Foundation | Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments |
DE3421468A1 (en) * | 1984-06-08 | 1985-12-19 | Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim | LIPID NANOPELLETS AS A CARRIER SYSTEM FOR MEDICINAL PRODUCTS FOR PERORAL USE |
US5122127A (en) * | 1985-05-01 | 1992-06-16 | University Of Utah | Apparatus and methods for use in administering medicaments by direct medicament contact to mucosal tissues |
US5288497A (en) * | 1985-05-01 | 1994-02-22 | The University Of Utah | Compositions of oral dissolvable medicaments |
US4760059A (en) * | 1985-08-05 | 1988-07-26 | Hoffmann-La Roche Inc. | Rectal dosage form |
US4976949A (en) * | 1985-10-25 | 1990-12-11 | The University Of Michigan | Controlled release dosage form |
US4847092A (en) * | 1985-11-12 | 1989-07-11 | Eli Lilly And Company | Orally administerable sustained release pharmaceutical formulations |
US4797286A (en) * | 1985-11-12 | 1989-01-10 | Eli Lilly And Company | Orally administerable sustained release pharmaceutical formulations |
US5112619A (en) * | 1985-11-12 | 1992-05-12 | Eli Lilly And Company | Orally administerable sustained release pharmaceutical formulation |
US4849227A (en) * | 1986-03-21 | 1989-07-18 | Eurasiam Laboratories, Inc. | Pharmaceutical compositions |
US4814183A (en) * | 1987-08-31 | 1989-03-21 | Merck & Co., Inc. | Device for the controlled release of drugs with Donnan-like modulation by charged insoluble resins |
US4795644A (en) * | 1987-08-03 | 1989-01-03 | Merck & Co., Inc. | Device for pH independent release of drugs through the Donnan-like influence of charged insoluble resins |
US4944944A (en) * | 1987-11-19 | 1990-07-31 | Oklahoma Medical Research Foundation | Dietary compositions and methods using bile salt-activated lipase |
HU206367B (en) * | 1988-04-30 | 1992-10-28 | Sandoz Ag | Process for producing acid addition salts of steroid carboxylic acid-amidated taurine and glycine, as well as pharmaceutical compositions comprising such salts |
DE3830932A1 (en) * | 1988-09-12 | 1990-03-15 | Diamalt Ag | 2-HYDROXY-N, N, N-TRIMETHYL ETHANAMINIUM SALTS OF 5SS-CHOLAN-24-ACID DERIVATIVES |
CA2013755C (en) * | 1989-04-05 | 1993-11-30 | Simon Benita | Medicinal emulsions |
GB8909022D0 (en) * | 1989-04-20 | 1989-06-07 | Cortecs Ltd | Pharmaceutical compositions |
JP3273785B2 (en) * | 1990-08-13 | 2002-04-15 | ダブリュー. イェスエア,デービッド | Mixed lipid-bicarbonate colloid particles for drug or heat source delivery |
IT1245891B (en) * | 1991-04-12 | 1994-10-25 | Alfa Wassermann Spa | CONTROLLED RELEASE PHARMACEUTICAL FORMULATIONS FOR ORAL USE GAS RESISTANT CONTAINING BILE ACIDS AND THEIR SALTS. |
IT1257793B (en) * | 1992-05-18 | 1996-02-13 | PHARMACEUTICAL COMPOSITION BASED ON BILIARY ACIDS IN MICROGRANULES WITH CONTROLLED RELEASE | |
US5262172A (en) * | 1992-06-19 | 1993-11-16 | Digestive Care Inc. | Compositions of gastric acid-resistant microspheres containing buffered bile acids |
US5234697A (en) * | 1992-06-22 | 1993-08-10 | Digestive Care Inc. | Compositions of gastric acid-resistant microspheres containing salts of bile acids |
-
1992
- 1992-06-12 GB GB929212511A patent/GB9212511D0/en active Pending
-
1993
- 1993-06-11 ES ES93913350T patent/ES2107038T3/en not_active Expired - Lifetime
- 1993-06-11 AT AT93913350T patent/ATE157865T1/en not_active IP Right Cessation
- 1993-06-11 JP JP6501285A patent/JPH07508724A/en active Pending
- 1993-06-11 EP EP93913350A patent/EP0644757B1/en not_active Expired - Lifetime
- 1993-06-11 US US08/338,548 patent/US5942248A/en not_active Expired - Fee Related
- 1993-06-11 CA CA002137573A patent/CA2137573C/en not_active Expired - Fee Related
- 1993-06-11 SG SG1996000281A patent/SG63537A1/en unknown
- 1993-06-11 AU AU43456/93A patent/AU671285B2/en not_active Ceased
- 1993-06-11 DK DK93913350.0T patent/DK0644757T3/en active
- 1993-06-11 DE DE69313849T patent/DE69313849T2/en not_active Expired - Fee Related
- 1993-06-11 NZ NZ253262A patent/NZ253262A/en unknown
- 1993-06-11 WO PCT/GB1993/001247 patent/WO1993025192A1/en active IP Right Grant
-
1997
- 1997-12-02 GR GR970403215T patent/GR3025565T3/en unknown
-
1998
- 1998-03-09 HK HK98101914A patent/HK1002828A1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
HK1002828A1 (en) | 1998-09-18 |
DE69313849T2 (en) | 1998-03-19 |
ES2107038T3 (en) | 1997-11-16 |
GR3025565T3 (en) | 1998-03-31 |
DE69313849D1 (en) | 1997-10-16 |
ATE157865T1 (en) | 1997-09-15 |
AU4345693A (en) | 1994-01-04 |
EP0644757B1 (en) | 1997-09-10 |
JPH07508724A (en) | 1995-09-28 |
EP0644757A1 (en) | 1995-03-29 |
CA2137573C (en) | 1999-01-26 |
GB9212511D0 (en) | 1992-07-22 |
US5942248A (en) | 1999-08-24 |
SG63537A1 (en) | 1999-03-30 |
AU671285B2 (en) | 1996-08-22 |
NZ253262A (en) | 1996-06-25 |
DK0644757T3 (en) | 1997-10-13 |
WO1993025192A1 (en) | 1993-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2137573A1 (en) | Pharmaceutical compositions containing nsaid and bile acids | |
PL338334A1 (en) | Pharmaceutic composition in the form of self-emulsifiable formulation of lipophilic compounds | |
CA2330500A1 (en) | Pharmaceutical compositions capable of being gelled | |
DE69426831D1 (en) | RAPAMYCIN HETEROCYCLIC ESTERS AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | |
ATE61050T1 (en) | PYRIDAZINAMINES EFFECTIVE AGAINST VIRUSES. | |
CA2420222A1 (en) | Orally administered peptides to ameliorate atherosclerosis | |
EP1221326A3 (en) | Nitric oxide donors capable of reducing toxicity from drugs | |
AU4886896A (en) | Improvements in or relating to organic compositions | |
CA2106172A1 (en) | Use of 2-(3,4-Dimethoxycinnamoyl)Aminobenzoic Acid for the Treatment of Restenosis Associated with Coronary Intervention | |
BR0007294A (en) | Improved pharmaceutical formulations | |
CA2283322A1 (en) | Starter kit containing nicotinic acid compositions | |
CA2382292A1 (en) | Ibuprofen-containing softgels | |
NZ515757A (en) | Amorphous compounds and their pharmaceutical compositions | |
DK0525111T3 (en) | Anti-inflammatory hydroxamic acids and N-hydroxyureas | |
AU1843397A (en) | Dihydrobenzofuran and related compounds useful as anti-inflammatory agents | |
CA2052901A1 (en) | Pharmacologically enhanced formulations | |
CA2120048A1 (en) | Pharmaceutical composition having analgesic activity | |
CA2258725A1 (en) | Analogues or derivatives of quercetin (prodrugs) | |
IL94080A0 (en) | Protected amino acids and their preparation | |
CA2178163A1 (en) | Water soluble granular compositions comprising an imidazolinone herbicide and a base | |
CA2379696A1 (en) | Inhibition of renal uptake of radiomolecules with a combination of lysine and arginine | |
EP0626170A3 (en) | Stabilisation of pharmacologically active compounds in sustained release compositions. | |
RU2002113885A (en) | Ibuprofen ointment, prepared on a polyethylene oxide basis, has anti-inflammatory effect | |
AU5768294A (en) | Compositions of iodobenzoic acid derivatives in film-forming materials for visualization of the gastrointestinal tract | |
MX9606520A (en) | Fungicidal mixtures. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |